The Board expressed their condolences on the death of Ms Vicky Phelan.
The CEO informed the Board that Ms Gráinne Cunningham-O’Brien has now been appointed to the role of Confidential Recipient and Mr Joseph Duggan has been appointed National Director Internal Audit.
The Board reviewed and discussed the key aspects of the CEO monthly report and supporting papers, including the Board Strategic Scorecard Report, which had been circulated prior to the meeting.
The Board discussed the following strategic areas of the CEO report:
Winter Viruses
The CEO advised the Board that this winter there are three main viruses: Respiratory Syncytial Virus (RSV), Influenza and COVID-19 in circulation, and due to the relatively mild weather to date, this has mitigated against transmission, but should be aware of expected spikes of cases with consequent health system pressures should there be a protracted period of cold weather.
Monkeypox
The Board were informed that the booking portal went live on 24th November with 70% of bookings received. Intra-dermal training of nurse vaccinators across Central Vaccination Centres are now complete and training has commenced this week.
National Screening Service
The Board welcomed the publication of Dr Gabriel Scally’s final report on the 23 November 2022, noting that the report confirms that women can have confidence in Irelands cervical screening programme. The Board held a discussion on the implementation of the recommendations of the Scally Report, the importance of meaningful patient and stakeholder involvement and transparent reporting structures within the National Screening Services.
Patient Safety Bill
The Chair and Deputy Chair informed the Board of the meeting that was held with the Minister for Health on 17 November 2022 regarding the Patient Safety Bill and the Board’s concerns with the intention to introduce a notifiable incident directly relating to cancer screening services, noting that this proposal might impact the screening programmes resulting in difficulties resourcing the programmes, reduced effectiveness and poorer clinical outcomes. The CEO advised that there is ongoing engagement with the DoH in relation to this.
National Strategy for Accelerating Genetic & Genomic Medicine in Ireland
The Board welcomed this much needed Strategy that is filling a long term policy gap, which had been circulated prior to the meeting. The Strategy which is due to be launched on the 13 December outlines the approach for developing sustainable patient and family centred genetics and genomics service that can be accessed equitably across the country and across the lifespan of patients. The service will be supported by strong governance, a skilled workforce, pioneering research and innovation, and trusted partnerships. The Board discussed the Strategy stating that good and transparent data governance is essential and that it will bring change that will require change management, including during the RHA development. The Board outlined that there is genetics and genomics medicine and research ongoing outside of the HSE that will need to be engaged with, including private healthcare providers and non-profit organisations. The Board noted that PPI element of the strategy was very welcome and the presenters agreed to obtain feedback from the patient representatives on their experiences of the development process that would inform the patient/service user involvement in the next steps of implementation.
The Board noted that the Safety and Quality Committee will be updated regularly on progress.
Test & Trace
The CEO advised the Board that the Test and Trace function continues to prepare for the transition to the future clinical, public health and surveillance led model, and are engaging with the DoH to ensure that appropriate planning and stakeholder engagement is in place before commencing the transition. Advice has been received from the DoH concerning expired vaccines, and continued action is being taken in relation to vaccinations of healthcare workers.
Ukrainian Update
The CEO informed the Board that the Department of Children, Equality, Disability, Integration and Youth (DCEDIY), in conjunction with Central Statistics Office, are developing a standardised set of arrival scenarios for use by all Government departments in 2023. These have not been available to inform planning assumptions for Health in 2023, however, it has been confirmed that arrival scenarios in use by HSE align broadly with those of DCEDIY. The design of the future service delivery model for Ukrainian and International Protection Applicants (IPA) populations is nearing completion. The model seeks to enable the same access to services as is available to the existing population whilst addressing the specific health needs of both populations
Disability Services
The Progressing Disability Services Roadmap is currently being developed which will set out the actions being progressed by the HSE to improve services for children with disabilities and developmental delays as well as their families. This process is concluding, and a draft roadmap will be presented to the Performance and Delivery Committee in December for consideration with the aim to complete the development of the plan before the end of 2022.
National Ambulance Service (NAS) Strategy
The CEO presented to the Board the NAS 10 year Strategy (2021-2031), which sets out the vision and objectives for the future of the National Ambulance Service (NAS). This is aligned to the HSE Corporate Strategy, which can inform future investment decisions and which sets up NAS as a potent enabler of the Slaintecare vision to treat more people closer to home. The Strategy has been reviewed by the Audit and Risk Committee on 09 November 2022 and supported by the Performance and Delivery Committee on 18 November 2022. The CEO advised that DoH have indicated that the Minister is bringing a Memorandum to Government seeking support for a programme of investment in NAS over the coming years, based on this strategy. The Board welcomed the development of the strategy and noted that it will be submitted to the Minister for Health.
Waiting Lists
The Board considered the report provided on the implementation of the 2022 Waiting List Action Plan which had set an ambitious improvement in waiting lists and waiting times. The Board noted that, overall, progress against targets has been slower than projected and as a result, the total number of patients on the outpatient waiting list is 14% behind target and the total number of patients waiting on the inpatient / day case waiting list is 6% behind target. The Board noted the progress made in relation to reducing the number of patients waiting longer than the 2022 maximum wait time targets set.
The CEO and COO confirmed ongoing engagement with the delivery system has identified a number of contributing factors, including the continued impact of COVID-19 and ED pressures, bed capacity, increased staff absences and capacity deficits within a number of specialties (e.g. Orthopaedics, ENT, Rheumatology, etc.). In the last 13 weeks, however, core activity volumes have been ahead of target and improvements in both the total number of people waiting for care and the number of people waiting longer than the maximum wait time targets have been achieved.
The COO informed the Board of a number of remedial actions that are being progressed, including the establishment of an Acute Operations Oversight Group chaired by the National Director of Acute Operations and weekly performance meetings with Hospital Groups. Additional administrative resources have also been provided to increase HSE’s capacity for NTPF commissioning and validation, with 10 additional sites commencing validation for patients waiting longer than three months.
The COO noted that while we are seeing progress in many individual hospitals in increasing activity, and thereby in reducing waiting lists, our challenge is now to replicate these success stories across the health system.
The Board welcomed the recent additional actions that the CEO and the executive had put in place to improve the current situation and requested management to make a concerted effort to enable progress on waiting lists to year end, albeit recognising that for a number of reasons, including the higher than anticipated impact of COVID, it would not be practical to fully achieve the targets by year end.
Reconfiguration of Services at Our Lady’s Hospital Navan (OLHN)
The Board discussed the correspondence received from the Minister for Health dated 24th November 2022 and confirmations received from the Secretary General to the CEO, noting that the DoH is satisfied with the HSE’s proposal to proceed with the enhanced bypass protocol for OLHN to include those who are critically or seriously unwell or likely to deteriorate, from the week of 12 December 2022.
It was noted that this is on the basis of the clarifications on the bypass protocol previously provided by the HSE and conditional on shared clinical governance/repatriation arrangements being agreed in advance with both hospitals.
The CEO informed the Board that an implementation group, led by ND Acutes, Mary Day and Dr Mike O’Connor, are continuing to oversee the implementation of the bypass protocol.
A response to the recent correspondence from the Minister, regarding progression of the review’s recommendations, will be prepared.
Climate Action Strategy and Implementation Plan
The Climate Action Strategy and Implementation Plan, which had been circulated prior to the meeting was welcomed by the Board noting that it had been considered and supported by the Audit & Risk Committee. The Board were informed that the Plan is an essential enabler to providing resilient healthcare infrastructure to support current and future service needs, therefore both supporting the objectives of Sláintecare and helping to build public trust amidst a rapidly changing climate and environment.
The Board welcomed the development of the Climate Action Strategy and Implementation Plan. The next steps for the Strategy’s implementation include the establishing of a Programme Management Office and allocating the resources to mobilise implementation, appointing Workstream Leads and members and communicating their roles, responsibilities and Workstream deliverables and to identify Subject Matter Experts and appropriate external support to assist the Workstreams and Steering Group.
Capital Strategy and Implementation Plan
The CSO presented the Capital Strategy and Implementation Plan proposal, which had been considered and supported by the Audit & Risk Committee. The Strategy sets the direction for the future development and management of Healthcare estate. The associated Implementation Plan sets out the key details for the successful implementation of the Strategy, allowing the HSE Capital and Estates team to establish the Programme and progress to implementation as soon as possible.
The Board welcomed the Strategy and Implementation Plan.
In relation to a request from the Board, the ND Estates agreed to circulate a list of derelict properties to the Board.
Board Strategic Scorecard
The CEO presented the Board Strategic Scorecard, as circulated prior to the meeting and the Board discussed the ratings in relation to key programmes and priorities. It was noted that the overall average rating on the eligible 20 scorecards is 2.65, down from the October 2022 rating of 2.75 due to a change of rating returned on two scorecards. These were Reform of Primary Care, Community and ECC changed from a 3 to a 2 and Planning and Implementation of Regional Health Areas changed from a 3 to a 2. All other scorecard ratings have remained constant.
Following the discussion, the Board approved the Board Strategic Scorecard for submission to the Minister.